Markets:

Overview

News

Currencies

International

Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

19.09 +0.51 (+2.72%)

Streaming Delayed Price Updated: 9:35 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Keros Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >

Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗

December 25, 2025

Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry.

Via Chartmill

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗

June 10, 2025

BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.

Via Benzinga

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗

May 29, 2025

Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.

Via Benzinga

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗

April 11, 2025

Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.

Via Benzinga

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗

April 10, 2025

Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control.

Via Benzinga

Analyst Expectations For Keros Therapeutics's Future ↗

February 27, 2025

Via Benzinga

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗

January 17, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 10, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗

April 10, 2025

The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control...

Via Stocktwits

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗

April 10, 2025

Via Benzinga

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗

April 10, 2025

Via Benzinga

Where Keros Therapeutics Stands With Analysts ↗

December 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 10, 2025

Via Benzinga

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗

April 01, 2025

Via Benzinga

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm

January 24, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)

January 22, 2025

From Kirby McInerney LLP

Via Business Wire

Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗

January 15, 2025

Via Benzinga

Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗

January 15, 2025

Via Benzinga

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Via Stocktwits

Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS

December 17, 2024

Via ACCESSWIRE

Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS

December 16, 2024

Via ACCESSWIRE

Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud

December 16, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗

December 12, 2024

Via Benzinga

Topics Stocks

Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗

December 12, 2024

Via Benzinga

Nasdaq Down 50 Points; US Initial Jobless Claims Rise ↗

December 12, 2024

Via Benzinga

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why ↗

December 12, 2024

Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025.

Via Benzinga

Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study ↗

December 12, 2024

The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.

Via Investor's Business Daily

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst ↗

December 03, 2024

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.